

## Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: June 18, 2025: 9:15 a.m. – 1:30 p.m. (Central Time)

Minutes prepared by: Naana Osei-Boateng and Dave Hoang

Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

### Attendance

---

- Members in attendance: Margaret Artz, RPh, PhD; Jacques Beasley; Arthur Beisang, MD; Mary Mescher Benbenek, PhD, APRN; Emily Jaeger, PharmD; Kathryn Lombardo, MD; Kelly Ruby, PharmD; Emma Ryan, PharmD; Sheila Scheuer, PharmD; Sofia Shrestha, PharmD; Sandra Widhalm Murphy, RPh; Stuart Williams, JD; Jena Wirt, DO. Julie Wolfgram, DNP, FNP
- Members absent: Monica Brands, RPh; Katherine Montag Schafer, PharmD; Amirala Pasha, DO, JD; Romie Tinsay, MD.
- DHS staff present: Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Nathan Chomilo, MD; Aaron Drake, RPh
- Others in attendance: Naana Osei-Boateng, PharmD; Chloe Groomes, PharmD; Andrew Wherley, PharmD

### Report of the Chair

---

- Stuart Williams presided over the meeting. New member Emma Ryan was introduced.

### Approval of Minutes

---

- The DFC approved the minutes from the March 2025 DFC meeting.

### DHS Housekeeping

---

- None

### Old Business

---

- None

### New Business

---

- DHS congratulated Dr. K Lombardo on her upcoming retirement and thanked her for her tireless dedication and service to the DFC.
- DHS informed DFC that Dr. Amirala Pasha has resigned due to relocation and thanked Dr. Pasha for his service to the DFC.

- DHS will soon post on the Secretary of State websites open seats vacated by Dr. Lombardo and Dr. Pasha.

### **Drugs for Continued Prior Authorization (PA)**

---

- The committee discussed Rhofade and recommended to DHS by a unanimous vote that Rhofade remain on PA with the proposed criteria:
- The committee discussed Ryzumvi and recommended to DHS by a unanimous vote that Ryzumvi remain on PA with the proposed criteria.

### **Specialty Drugs for Continued PA**

---

- The committee discussed Casgevvy and recommended to DHS by a unanimous vote that Casgevvy remain on PA with the proposed criteria.
- The committee discussed Attruby and recommended to DHS by a unanimous vote that Attruby remain on PA with the proposed criteria.
- The committee discussed Hymravz and recommended to DHS by a unanimous vote that Hymravz remain on PA with the proposed criteria.
- The committee discussed Alhemo and recommended to DHS by a unanimous vote that Alhemo remain on PA with the proposed criteria.
- The committee discussed Alyftrek and recommended to DHS by a unanimous vote that Alyftrek remain on PA with the proposed criteria.
- The committee discussed Crenessity and recommended to DHS by a unanimous vote that Crenessity remain on PA with the following caveat- DHS to bring the matter before the DFC after 6 months for consideration.
- The committee discussed Prevymis and recommended to DHS by a unanimous vote that Prevymis remain on PA with the proposed criteria.
- The committee discussed Journavx and recommended to DHS by a unanimous vote that Journavx remain on PA with the proposed criteria.

### **Preferred Drug List (PDL) Review**

---

#### **DISCUSSION ITEMS:**

- The committee discussed the Angiotensin Modulators therapeutic class and recommended the following to the department by a unanimous vote:
  - QUINAPRIL (ORAL) to be moved on the PDL as NONPREFERRED.
- The committee discussed the Antibiotics, Inhaled therapeutic class and recommended the following to the department by a majority vote:
  - ARIKAYCE (INHALATION) to be added to the PDL as NONPREFERRED.
- The committee discussed the Antifungals, Oral therapeutic class and recommended the following to the department by a unanimous vote:
  - VORICONAZOLE TABLET (ORAL) to be added to the PDL as PREFERRED.
  - DIFLUCAN TABLET (ORAL), ORAVIG (BUCCAL), VFEND TABLET (ORAL), VFEND SUSPENSION (ORAL) and VORICONAZOLE SUSPENSION (ORAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Antifungals, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - NAFTIFINE CREAM (TOPICAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Antivirals, General therapeutic class; a new addition to the PDL and recommended the following to the department by a unanimous vote:
  - PAXLOVID TAB DOSE PACK (ORAL) to be added to the PDL as PREFERRED.
- The committee discussed the Beta-Blockers therapeutic class recommended the following to the department by a unanimous vote:
  - BISOPROLOL HCTZ (ORAL), NEBIVOLOL (ORAL) and PROPRANOLOL/HCTZ (ORAL) be moved on the PDL to PREFERRED.
  - BYSTOLIC (ORAL) and PINDOLOL (ORAL) to be added to the PDL as NONPREFERRED.
  - CORGARD (ORAL) to be removed from the PDL.
- The committee discussed the Bone Resorption Suppression and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - BINOSTO (ORAL) to be added to the PDL as NONPREFERRED.
  - BONIVA (ORAL) and ETIDRONATE DISODIUM (ORAL) to be removed from the PDL.
- The committee discussed the BPH Treatments therapeutic class and recommended the following to the department by a unanimous vote:
  - TEZRULY (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Cephalosporins and Related Antibiotics therapeutic class and recommended the following to the department by a unanimous vote:
  - AUGMENTIN 125 SUSPENSION (ORAL) and AUGMENTIN ES-600 SUSPENSION (ORAL) to be added to the PDL as NONPREFERRED.
  - AUGMENTIN XR (ORAL) and KEFLEX (ORAL) to be removed from the PDL.
- The committee discussed the COPD Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - TUDORZA PRESSAIR (INHALATION) to be moved on the PDL to NONPREFERRED.
  - UMECLIDINIUM-VILANTEROL ELLIPTA (INHALATION) to be added to the PDL as NONPREFERRED.
- The committee discussed the Epinephrine, Self-Injected therapeutic class and recommended the following to the department by a unanimous vote:
  - SYMJEPI to be moved on the PDL to NONPREFERRED.
  - NEFFY SPRAY (NASAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Hypoglycemics, Incretin Mimetics/Enhancers therapeutic class and recommended the following to the department by a unanimous vote:
  - TRULICITY (SUBCUTANE.) to be moved on the PDL to PREFERRED.
  - EXENATIDE PEN (SUBCUTANE.) to be added to the PDL as NONPREFERRED.
  - BYDUREON BCISE (SUBCUTANE.) and BYETTA PENS (SUBCUTANE.) to be removed from the PDL.
- The committee discussed the Lipotropics, Other therapeutic class and recommended the following to the department by a unanimous vote:
  - EUCRISA (TOPICAL) to be moved on the PDL to PREFERRED.
  - EBGlySS (SUBCUTANEOUS), NEMLUVIO PEN (SUBCUTANEOUS) and ZORYVE FOAM (TOPICAL) to be added to the PDL as NONPREFERRED
- The committee discussed the COPD Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - TRYNGOLZA (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED.
  - LOVAZA (ORAL) to be removed from the PDL.

#### **CONSENT AGENDA ITEMS:**

The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be approved as presented with no changes.

### Other Business

---

- None

### Adjournment

---

- The meeting was adjourned at approximately 12:27 p.m. Central Time.